Article
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Journal of acquired immune deficiency syndromes (1999) - 1 Feb 2013
Vernazza Pietro, Wang Cunshan, Pozniak Anton, Weil Elizabeth, Pulik Piotr, Cooper David A, Kaplan Richard, Lazzarin Adriano, Valdez Hernan, Goodrich James, Mori Julie, Craig Charles, Tawadrous Margaret
Abstract excerpt
OBJECTIVE: A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive HIV-1-infected patients. METHODS: This ongoing international, multicenter, double-blind, randomized, Phase IIb exploratory study evaluates the efficacy and safety of 2 doses of lersivirine or 1 of efavirenz, each combined with tenofovir disoproxil fumarate/emtricitabine. Patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.